Marios K Georgakis1, Georgios Tsivgoulis2,3, Dimitrios Spinos4, Nikolaos G Dimitriou4, Athanasios P Kyritsis5, Ulrich Herrlinger6, Eleni Th Petridou4,7. 1. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Str., 11745, Athens, Greece. mgeorgakis91@gmail.com. 2. Second Department of Neurology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 3. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. 4. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 75 M. Asias Str., 11745, Athens, Greece. 5. Department of Neurology, University Hospital of Ioannina, Medical School, University of Ioannina, Ioannina, Greece. 6. Division of Neurooncology, Department of Neurology, University Medical Center Bonn, Bonn, Germany. 7. Unit of Clinical Epidemiology, Karolinska Institute, Stockholm, Sweden.
Abstract
INTRODUCTION: Gliomatosis cerebri (GC) is a rare fatal widespread infiltrating CNS tumor. As consistent disease features have not been established, the tumor comprises a diagnostic challenge. METHODS: We conducted a systematic literature search for published case reports and case series on patients with histologically confirmed GC. Clinical, diagnostic, neuroimaging, histopathological, and molecular data on individual or summary patient level were extracted and analyzed. RESULTS: A total of 274 studies were identified, including 866 patients with individual-level data and 782 patients with summary data (58.9% males, mean age 43.6 years). Seizures (49.8%) were the most common presenting symptom followed by headache (35.9%), cognitive decline (32.2%), and focal motor deficits (32%). Imaging studies showed bilateral hemisphere involvement in 65%, infratentorial infiltration in 29.9% and a focal contrast-enhanced mass (type II GC) in 31.1% of cases. MRI (extensive hyperintensities in T2/FLAIR sequences) and MR spectroscopy (elevated choline, creatinine, and myoinositol levels; decreased NAA levels) showed highly consistent findings across GC patients. Low-grade and anaplastic astrocytoma were the most prevalent diagnostic categories, albeit features of any histology (astrocytic, oligodendroglial, oligoastrocytic) and grade (II-IV) were also reported. Among molecular aberrations, IDH1 mutation and MGMT promoter methylation were the most commonly reported. Increasing time elapsed from symptom onset to diagnosis comprised the only independent determinant of the extent of CNS infiltration. CONCLUSION: A distinct clinical, neuroimaging, histopathological, or molecular GC phenotype is not supported by current evidence. MRI and MR spectroscopy are important tools for the diagnosis of the tumor before confirmation with biopsy.
INTRODUCTION:Gliomatosis cerebri (GC) is a rare fatal widespread infiltrating CNS tumor. As consistent disease features have not been established, the tumor comprises a diagnostic challenge. METHODS: We conducted a systematic literature search for published case reports and case series on patients with histologically confirmed GC. Clinical, diagnostic, neuroimaging, histopathological, and molecular data on individual or summary patient level were extracted and analyzed. RESULTS: A total of 274 studies were identified, including 866 patients with individual-level data and 782 patients with summary data (58.9% males, mean age 43.6 years). Seizures (49.8%) were the most common presenting symptom followed by headache (35.9%), cognitive decline (32.2%), and focal motor deficits (32%). Imaging studies showed bilateral hemisphere involvement in 65%, infratentorial infiltration in 29.9% and a focal contrast-enhanced mass (type II GC) in 31.1% of cases. MRI (extensive hyperintensities in T2/FLAIR sequences) and MR spectroscopy (elevated choline, creatinine, and myoinositol levels; decreased NAA levels) showed highly consistent findings across GC patients. Low-grade and anaplastic astrocytoma were the most prevalent diagnostic categories, albeit features of any histology (astrocytic, oligodendroglial, oligoastrocytic) and grade (II-IV) were also reported. Among molecular aberrations, IDH1 mutation and MGMT promoter methylation were the most commonly reported. Increasing time elapsed from symptom onset to diagnosis comprised the only independent determinant of the extent of CNS infiltration. CONCLUSION: A distinct clinical, neuroimaging, histopathological, or molecular GC phenotype is not supported by current evidence. MRI and MR spectroscopy are important tools for the diagnosis of the tumor before confirmation with biopsy.
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Martin Glas; Oliver Bähr; Jörg Felsberg; Katja Rasch; Dorothee Wiewrodt; Martin Schabet; Matthias Simon; Horst Urbach; Joachim P Steinbach; Johannes Rieger; Rolf Fimmers; Michael Bamberg; Thomas Nägele; Guido Reifenberger; Michael Weller; Ulrich Herrlinger Journal: Ann Neurol Date: 2011-06-27 Impact factor: 10.422
Authors: M Bendszus; M Warmuth-Metz; R Klein; R Burger; C Schichor; J C Tonn; L Solymosi Journal: AJNR Am J Neuroradiol Date: 2000-02 Impact factor: 3.825
Authors: Juan A Guzmán-de-Villoria; Javier Sánchez-González; Lucia Muñoz; Santiago Reig; Carlos Benito; Pedro García-Barreno; Manuel Desco Journal: AJR Am J Roentgenol Date: 2007-03 Impact factor: 3.959
Authors: Selby Chen; Shota Tanaka; Caterina Giannini; Jonathan Morris; Elizabeth S Yan; Jan Buckner; Daniel H Lachance; Ian F Parney Journal: J Neurooncol Date: 2013-01-23 Impact factor: 4.130
Authors: Ulrich Herrlinger; David T W Jones; Martin Glas; Elke Hattingen; Dorothee Gramatzki; Moritz Stuplich; Jörg Felsberg; Oliver Bähr; Gerrit H Gielen; Matthias Simon; Dorothee Wiewrodt; Martin Schabet; Volker Hovestadt; David Capper; Joachim P Steinbach; Andreas von Deimling; Peter Lichter; Stefan M Pfister; Michael Weller; Guido Reifenberger Journal: Acta Neuropathol Date: 2015-10-22 Impact factor: 17.088